API | olokizumab

olokizumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Olokizumab is an immunomodulator. It binds to interleukin 6. Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

olokizumab

None

More Chemistry

Pharmacology

Mechanisms of Action:
- Interleukin-6 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cdp6038 | cdp 6038 | cdp-6038 | olokizumab

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Arthritis (Phase 1/Phase 2)

Arthritis, Rheumatoid (Phase 3)

COVID-19 (Phase 2/Phase 3)

Crohn Disease (Phase 2)

Healthy Volunteers (Phase 1)

Pharmacokinetics (Phase 1)

ST Elevation Myocardial Infarction (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue